Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B

Date
2007
Author
Herrmann, Eva
Karayalcin, Selim
Flisiak, Robert
van 't Veen, Annemarie
de Man, Robert A.
Schalm, Solko W.
Janssen, Harry L. A.
Haagmans, Bart L.
Cakaloglu, Yilmaz
ter Borg, Martijn J.
Hansen, Bettina E.
Zeuzem, Stefan
Metadata
Show full item record
Abstract
Background: Pegylated interferon alpha 2b (PEG-IFN-alpha 2b) is effective for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, although its mechanism of action remains unclear. HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-a2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha 2b monotherapy.
URI
http://hdl.handle.net/20.500.12627/70140
Collections